Despite of the differences of clinical characteristics in TCGA cohort, recurrent CLDN18-ARHGAP fusion (13/295) was also significantly enriched in patients at a younger age (60.2 ± 10.7 years vs. 66.8 ± 10.7 years, P = 0.03, Logistic regression test), females (2.3% in male vs. 8% in female, P = 0.03, Logistic regression test), and diffuse type of gastric cancer (1.1% in intestinal, 11.8% in diffuse, P = 0.001, Logistic regression test) (Fig. 4a–c and Supplementary Table 4). The gene discussed is CLDN18; the disease is gastric cancer.